3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers : effect of 6,7-distribution on potency and tissue selectivity
De Tullio, Pascal; Boverie, S.; Becker, B.et al.
2005 • In Journal of Medicinal Chemistry, 48, p. 4990-5000
De Tullio, Pascal ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Boverie, S.
Becker, B.
Antoine, M.-H.
Nguyen, Q.-A.
Francotte, Pierre ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Counerotte, Stéphane ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Sebille, S.
Pirotte, Bernard ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Lebrun, P.
Language :
English
Title :
3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers : effect of 6,7-distribution on potency and tissue selectivity
Publication date :
2005
Journal title :
Journal of Medicinal Chemistry
ISSN :
0022-2623
eISSN :
1520-4804
Publisher :
American Chemical Society, Washington, United States - District of Columbia
Noma, A. ATP-regulated K+ channels in cardiac muscle. Nature 1983, 305, 147-148.
Cook, D. L.; Hales, C. N. Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature 1984, 377, 271-273.
Bernardi, H.; Fosset, A. M.; Lazdunski, M. Purification and affinity labelling of brain [3H]glibenclamide binding protein, a putative neuronal ATP-regulated K+ channel. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 9816-9820.
Standen, N. B.; Quayle, J. M.; Davies, N. W.; Brayden, J. E.; Huang, Y.; Nelson, M. T. Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science 1989, 245, 177-180.
Allard, B.; Lazdunski, M. Pharmacological properties of ATP-sensitive K+ channels in mammalian skeletal muscle cells. Eur. J. Pharmacol. 1993, 236, 419-426.
Quayle, J. M.; Nelson, M. T.; Standen, N. B. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 1997, 77, 1165-1232.
Bryan, J.; Aguilar-Bryan, L. The ABCs of ATP-sensitive potassium channels: more pieces of the puzzle. Curr. Opin. Cell Biol. 1997, 9, 553-559.
Seino, S.; Miki, T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
Babenko, A. P. ; Aguilar-Bryan, J. A. A view of SUR/Kir6.X K ATP channels. Annu. Rev. Physiol. 1998, 60, 667-687.
D'hahan, N.; Jacquet, H.; Moreau, C.; Catty, P.; Vivaudou, M. A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K+ channels by K+ channel openers. Mol. Pharmacol. 1999, 56, 308-315.
Seino, S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol. 1999, 61, 337-362.
Inagaki, N.; Gonio, T.; Clement, J. P. Reconstitution of IK ATP: an inward rectifier subunit plus a sulfonylurea receptor. Science 1995, 270, 1166-1170.
Hambrock, A.; Löfter-Walz, C.; Delabar, U.; Horio, Y.; Kurachi, Y.; Quast, U. ATP-sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP. Mol. Pharmacol. 1999, 55, 832-840.
Petersen, O. H.; Dunne, M. J. Regulation of K+ channels plays a crucial role in the control of insulin secretion. Pflueger's Arch. 1989, 414, S115-S120.
Lebrun, P. Flux cationiques dans les cellules B des îlots pancréatiques et investigations pharmacologiques (Cationic flux in B-cells from pancreatic islets and pharmacological investigations). Rev. Fr. Endocrinol. Clin., Nutr. Metab. 1993, 34, 241-254.
Kolb, H. A. Potassium channels in excitable and non-excitable cells. Rev. Physiol. Biochem. Pharmacol. 1990, 15, 51-79.
Brayden, J. E. Functional roles of KATP channels in vascular smooth muscles. Clin. Exp. Pharmacol. Physiol. 2002, 29, 312-316.
Seino, S.; Miki, T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog. Biophys. Mol. Biol. 2003, 81, 133-176.
Cotzee, W. A. ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc. 1992, 6, 201-208.
Mannhold, R. KATP channel openers: structure-activity relationships and therapeutic potential. Med. Res. Rev. 2004, 24, 213-266.
Coghlan, M. J.; Carroll, W. A.; Gopalakrishnan, M. Recent development in the biology and medicinal chemistry of potassium channel modulators: update from a decade progress. J. Med. Chem. 2001, 44, 1627-1653.
Lebrun, P.; Devreux, V.; Hermann, M.; Herchuelz, A. Similarities between the effects of pinacidil and diazoxide on ionic and secretory events in rat pancreatic islets. J. Pharmacol. Exp. Ther. 1989, 250, 1011-1018.
Quast, U. Do the K+ channel openers relax smooth muscle by opening K+ channels? Trends Pharmacol. Sci. 1993, 14, 332-337.
Atwal, K. S. Advances in the structure-activity relationships, mechanism of action, and therapeutic utilities of ATP-sensitive potassium channel openers. Drug Dev. Res. 1994, 33, 250-262.
Gribble, F. M.; Reimann, F. Pharmacological modulation of K(ATP) channels. Biochem. Soc. Trans. 2002, 30, 333-339.
Sebille, S.; de Tullio, P.; Boverie, S.; Antoine, M.-H.; Lebrun, P.; Pirotte, B. Recent development in the chemistry of potassium channel activators: the cromakalim analogues. Curr. Med. Chem. 2004, 11, 1213-1222.
Manley, P. W.; Quast, U. Structure-activity studies of potassium channel opening in pinacidil-types cyanoguanidines, nitroethenediamines, thioureas, and ureas. J. Med. Chem. 1992, 35, 2327-2340.
Pirotte, B.; Fontaine, J.; Lebrun, P. Recent advances in the chemistry of potassium channel openers. Curr. Med. Chem. 1995, 2, 537-582.
Björk, E.; Berne, C.; Kämpe, O.; Wibell, P.; Oskarsson, P.; Karlsson, F. A. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996, 45, 1427-1430.
Alemzadeh, R.; Langley, G.; Upchurch, L.; Smith, P.; Slonim, A. E. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J. Clin. Endocrinol. Metab. 1998, 83, 1911-1915.
Rasmussen, S. B.; Sorensen, T. S.; Hansen, J. B.; Mandrup-Poulsen, T.; Hornum, L.; Markholst, H. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cells function and mass in acutely diabetic BB rats. Horm. Metab. Res. 2000, 32, 294-300.
Cosgrove, K.; Antoine, M.-H.; Lee, A.; Barnes, P.; de Tullio, P.; Clayton, P.; McCloy, R.; De Lonlay, P.; Nihoul-Fékété, C.; Robert, J.; Saudubray, J.-M.; Rahier, J.; Lindley, K.; Hussain, K.; Aynsley-Green, A.; Pirotte, B.; Lebrun, P.; Dunne, M. BPDZ 154 activates adenosine 5′-triphosphate-sensitive potassium channels: in vitro studies using rodent insulin-secreting cells and islets isolated from patients with hyperinsulinism. J. Clin. Endcrinol. Metab. 2002, 87, 4860-4868.
Kumar, G. K.; Dastoor, F. C.; Robayo, J. R.; Razzaque, M. A. Side effects of diazoxide. JAMA, J. Am. Med. Assoc. 1976, 235, 275-276.
de Tullio, P.; Pirotte, B.; Lebrun, P.; Fontaine, J.; Dupont, L.; Antoine, M.-H.; Ouedraogo, R.; Khelili, S.; Maggetto, C.; Masereel, B.; Diouf, O.; Podona, T.; Delarge, J. 3- and 4-substituted 4H-pyrido[4,3-e]-1,2,4- thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation and structure-activity relationships. J. Med. Chem. 1996, 39, 937-948.
de Tullio, P.; Ouedraogo, R.; Dupont, L.; Somers, F.; Boverie, S.; Dogné, J.-M.; Delarge, J.; Pirotte, B. Synthesis and structural studies of 3-alkylamino-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides, a new class of heterocyclic compounds with therapeutic promises. Tetrahedron 1999, 55, 5419-5432.
Pirotte, B.; Ouedraogo, R.; de Tullio, P.; Khelili, S.; Somers, F.; Boverie, S.; Dupont, L.; Fontaine, J.; Damas, J.; Lebrun, P. 3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation. J. Med. Chem. 2000, 43, 1456-1466.
Pirotte, B.; Antoine, M.-H.; de Tullio, P.; Hermann, M.; Herchuelz, A.; Delarge, J.; Lebrun, P. A pyridothiadiazine (BPDZ 44) as a new and potent activator of ATP-sensitive K+ channels. Biochem. Pharmacol. 1994, 47, 1381-1386.
Boverie, S.; Antoine, M.-H.; de Tullio, P.; Somers, F.; Becker, B.; Sebille, S.; Lebrun, P.; Pirotte, B. Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino- 4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): introduction of heteroatoms in the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ring. J. Pharm. Pharmacol. 2001, 53, 973-980.
Ouedraogo, R.; Becker, B.; Boverie, S.; Somers, F.; Antoine, M.-H.; Pirotte, B.; Lebrun, P.; de Tullio, P. 2-Alkyl-3-alkylamino-2H-benzo-and pyridothiadiazine 1,1-dioxides: from K+ATP channel openers to Ca2+ channel blockers? Biol. Chem. 2002, 383, 1759-1768.
de Tullio, P.; Becker, B.; Boverie, S.; Dabrowski, M.; Wahl, P.; Antoine, M.-H.; Somers, F.; Sebille, S.; Ouedraogo, R.; Bondo Hansen, J.; Lebrun, P.; Pirotte, P. Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides. J. Med. Chem. 2003, 46, 3342-3353.
Lebrun, P.; Arkhammar, P.; Antoine, M.-H.; Nguyen, Q.-A.; Bondo Hansen, J.; Pirotte, B. A potent diazoxide analogue activating ATP-sensitive K + channels and inhibiting insulin release. Diabetologia 2000, 43, 723-732.
Dabrowski, M.; Ashcroft, F. M.; Ashfield, R.; Lebrun, P.; Pirotte, B.; Egebjerk, J.; Hansen, J. B.; Whal, P. The novel diazoxide analog 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide is a selective Kir6.2/SUR1 channel opener. Diabetes 2002, 51, 1896-1906.
Flemming, E. N.; Bodvarsdottir, T. B.; Worsaae, A.; MacKay, P.; Stiden, C. E.; Boonen, H. C.; Pridal, L.; Arkhammar, P. O. G.; Whal, P.; Ynddal, L.; Junager, F.; Dragsted, N.; Tagmose, T. M.; Mogensen, J. P.; Koch, A.; Treppendahl, S. P.; Hansen, J. B. 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4- benzothiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic B-cells. J. Med. Chem. 2002, 45, 4171-4187.
Topliss, J. G.; Yudis, M. D. Correlation of antihypertensive activity with structure in a series of 2H-1,2,4-benzothiadiazine 1,1-dioxides using the substituent constant approach. J. Med. Chem. 1972, 15, 394-403.
Wales, J. K.; Krees, S. V.; Grant, A. M.; Viktoria, J. K.; Wolff, F. W. Structure-activity relationships of benzothiadiazine compounds as hyperglycemic agents. J. Pharmacol. Exp. Ther. 1968, 164, 421-432.
de Tullio, P.; Pirotte, B.; Somers, F.; Boverie, S.; Lacan, F.; Delarge, J. Study of the ring closure reaction of o-aminosulfonamides with 1,1′-thiocarbonyldiimidazole. Tetrahedron 1998, 54, 4935-4942.
Peat, A. J.; Townsend, C.; Worley, J. F.; Allen, S. H.; Garrido, D.; Mertz, R. J.; Pfohl, J. L.; Terry, C. M.; Truax, J. F.; Veasey, R. L.; Thomson, S. A. Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4- benzothiadiazine-1,1-dioxide derivatives as KATP channel agonists. Bioorg. Med. Chem. Lett. 2002, 12, 2977-2980.
Ashcroft, F. M.; Rosrman, P. Electrophysiology of the pancreatic B-cell. Prog. Biophys. Mol. Biol. 1989, 54, 87-143.
Malaisse, W. J.; Lebrun, P. Mechanisms of sulfonylurea-induced insulin release. Diabetes Care 1990, 13, 9-17.
Lebrun, P.; Antoine, M.-H.; Herchuelz, A. Minireview: K+ channel openers and insulin release Life Sci. 1992, 51, 795-806.
Lebrun, P.; Malaisse, W. J.; Herchuelz, A. Evidence for two distinct modalities of Ca2+ influx into pancreatic B cell. Am. J. Physiol. 1982, 242, E59-E66.
Novelle, F. C.; Bell, S. C.; Abrams, E. L.; Ziegler, C.; Spargue, J. Diuretics: Aminobenzenedisulfonamides. J. Org. Chem. 1960, 25, 965-981.
Raffa, L.; Monzani, A.; Albasini, A. Halogen derivatives of 2-aminobenzenesulfonamide. Farmaco 1964, 19, 35-46.
Raffa, L.; Di Bella, M.; Ferrari, P.; Rinaldi, M.; Ferrari, W. Cardiovascular effect of derivatives of 1,2,4-benzothiadiazine 1,1-dioxide Farmaco 1974, 39, 411-423.
Becker, B.; Antoine, M.-H.; Nguyen, Q.-A.; Rigo, B.; Cosgrove, K. E.; Barnes, P. D.; Dunne, M. J.; Pirotte, B.; Lebrun, P. Synthesis and characterization of a quinolinonic compound activating ATP-sensitive K + channels in endocrine and smooth muscle tissues. Br. J. Pharmacol. 2001, 134, 375-385.
Lebrun, P.; Antoine, M.-H.; Ouedraogo, R.; Kane, C.; Dunne, M.; Hermann, M.; Herchuelz, A.; Masereel, B.; Delarge, J.; de Tullio, P.; Pirotte, B. Activation of ATP-dependent K+channels and inhibition of insulin release: effect of BPDZ 62. J. Pharmacol. Exp. Ther. 1996, 277, 156-162.
